A prohibitin-targeting peptidomimetic studied for selective disruption of white-fat vasculature in obesity models.
Pre-loaded with a typical Adipotide vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for Adipotide. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 250 mcg – 750 mcg | daily courses in primate protocols | subcutaneous or study-defined parenteral route | Nonhuman-primate efficacy/toxicology literature (Barnhart et al. and related summaries) Primate work reported weight-loss activity with dose-dependent renal tubular effects, more pronounced toward higher exposures (e.g., around 0.75 mg/kg class doses). Absolute mcg depends on animal mass. |
| 100 mcg – 1 mg | repeated dosing over days in preclinical protocols | intraperitoneal or study-defined | Mouse targeted-ablation studies (foundational Kolonin work and follow-ons) Mouse regimens are model-specific; primary papers should be used for exact molar amounts and vehicles. |
People searching this page also look for: adipotide peptide dosage chart, adipotide peptide dosage.
Adipotide is a designed peptidomimetic that couples a white-fat vascular homing motif (CKGGRAKDC) to a pro-apoptotic amphipathic sequence. The experimental concept is ligand-directed ablation of adipose endothelium via prohibitin targeting, which then reduces white-adipose mass in animal models. Foundational mouse work showed rapid fat loss and metabolic improvements, and later obese-monkey studies extended the efficacy signal to nonhuman primates.
The same primate literature is explicit about safety: dose-dependent renal proximal-tubule injury was the principal toxicity signal, generally described as monitorable and at least partly reversible after discontinuation, but clearly dose-limiting. That renal finding is central to any honest research summary and should neither be minimized nor sensationalized.
Research-grade adipotide is Research Use Only. It is not an FDA-approved weight-loss drug and is not for human consumption. Human development history includes early clinical interest, but educational RUO content must stay inside preclinical/reference framing.
The CKGGRAKDC motif homes to prohibitin displayed on white-adipose vasculature. Once localized, the D(KLAKLAK)2 effector disrupts mitochondrial membranes in targeted endothelial cells, triggering apoptosis. Loss of adipose blood supply is followed by resorption of white fat. Because the peptide is cleared through the kidney, tubular epithelial exposure is a plausible basis for the renal signals documented in primate toxicology.
targeted adipose vasculature ablation · prohibitin biology · obesity and insulin-resistance models · ligand-directed peptidomimetic design · renal safety pharmacology
Obesity-biology labs, vascular-targeting chemistry groups, and translational toxicology teams are the main audience. Interest is as much about targeted delivery platforms and on-target versus off-target injury as about weight endpoints alone.
Store lyophilized peptide cold, dry, and protected from light. Reconstitute shortly before use when possible; refrigerate solutions and avoid repeated freeze-thaw because pro-apoptotic peptidomimetics can be handling-sensitive.
Adipotide is rarely framed as a conventional peptide stack ingredient. Experimental comparisons are more often versus diet, leptin/insulin-sensitizer backgrounds, or other anti-obesity modalities. Any combination work must prioritize renal monitoring because nephrotoxicity is the dominant documented safety signal.
The questions people actually search for, answered plainly.
Published primate work used sub-mg/kg to under 1 mg/kg class daily exposures, with renal effects becoming more prominent at higher doses. Exact figures are species- and protocol-specific.
Dose-dependent renal proximal-tubule injury in nonhuman primates is the principal documented toxicity signal. Papers describe it as an important, monitorable limitation of the candidate.
It targets prohibitin on white-fat blood vessels and delivers a pro-apoptotic motif, damaging adipose endothelium so that fat tissue is resorbed secondarily.
No. Research-grade adipotide is RUO laboratory material and is not an FDA-approved weight-loss medication.
Obese-monkey research reported improvements in insulin resistance accompanying white-fat reduction, alongside the renal safety observations.
Because credible research education reports the full experimental record. For adipotide, efficacy and nephrotoxicity are inseparable parts of the published story.
No. It is a targeted peptidomimetic designed for ligand-directed vascular ablation, not a classic endocrine receptor agonist like GHRH or GLP-1 analogs.
Primary literature on Adipotide. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides